Xilio Therapeutics, INC 8-K filings

Xilio Therapeutics held its 2024 annual meeting of stockholders on June 13, 2024, where directors were elected and the company's accounting firm was ratified.

Xilio Therapeutics has increased its board size to nine members, appointing James Shannon, M.D., and Aoife Brennan, M.D., as new directors effective June 13, 2024.

Xilio Therapeutics reported its first quarter 2024 financial results, highlighted by pipeline advancements and strategic collaborations.

Xilio Therapeutics reported its fourth quarter and full year 2023 financial results, highlighted by a new licensing agreement with Gilead for its XTX301 program and plans to advance its clinical pipeline.

Xilio Therapeutics closed a $13.5 million private placement with Gilead Sciences, issuing 6,860,223 shares of common stock at $1.97 per share.

Xilio Therapeutics has entered into an exclusive licensing agreement with Gilead for its tumor-activated IL-12 program and secured $11.3 million through a private placement, while also announcing a strategic portfolio reprioritization.

Xilio Therapeutics has received a notice from Nasdaq stating that its stock price has fallen below the minimum bid price of $1.00, putting it at risk of delisting.